Clinical trials: Controlled Hypertension
Uncontrolled Hypertension
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.
- Trial name
- NCT07142356
- Testing
- RTN-001
- Where
- 34 sites in United States
- Volunteers
- 280 people
- Sponsor
- Retension Pharmaceuticals. Inc.
Primary Open-Angle Glaucoma (POAG)
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)
The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma.
- Trial name
- NCT06903156
- Testing
- Mexidol
- Where
- 7 sites in Russia
- Volunteers
- 102 people
- Sponsor
- Pharmasoft
Hypertension
A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension
The purpose of this study is to evaluate the effect of ION904 on plasma angiotensinogen (AGT) in participants with uncontrolled hypertension.
- Trial name
- NCT05314439
- Testing
- ION904
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Open-angle Glaucoma
Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty
Evaluation of intraocular pressure (IOP) lowering effect of two iStent stents versus a SLT procedure in subjects with open-angle glaucoma on one ocular hypotensive medication.
- Trial name
- NCT01444105
- Testing
- iStent, SLT
- Where
- Armenia
- Volunteers
- 80 people
- Sponsor
- Glaukos Corporation
Well-controlled Hypertension
Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-controlled Hypertensive Patients
The purpose of this study is to evaluate the influence of aspirin on blood pressure in well-controlled hypertensive patients who receive low dose aspirin at different times of the day
- Trial name
- NCT00386529
- Testing
- Aspirin enteric coated pellests 100mg
- Where
- South Korea
- Volunteers
- 191 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Trial name
- NCT00219063
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 844 people
- Sponsor
- Novartis
Hypercholesterolemia, Hypertension
Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan
The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.
- Trial name
- NCT03872232
- Testing
- Ezetimibe/Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
- Trial name
- NCT01785472
- Testing
- LCZ696, Olmesartan
- Where
- 50 sites in China, Hong Kong and 5 more
- Volunteers
- 1,438 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open-angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351.
- Trial name
- NCT03762369
- Testing
- CKD-351, Latanoprost, D930
- Where
- South Korea
- Volunteers
- 384 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Uncontrolled Hypertension
EuroNetrod HTN OFF-Med Study of Renal Denervation With NetrodTM Six-electrode Radiofrequency RDN System
This randomized controlled investigation aims to evaluate the efficacy and safety of the Netrod™ RDN system in patients with uncontrolled primary hypertension in the absence of antihypertensive medication, comparing the outcomes…
- Trial name
- EuroNetrod (NCT06722651)
- Testing
- Netrod™ six-electrode radiofrequency renal denervation system
- Where
- Switzerland
- Sponsor
- Shanghai Golden Leaf MedTec Co. Ltd
Elevated Intraocular Pressure
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to…
- Trial name
- TC-002-301 (NCT05165290)
- Testing
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- TearClear Corp
Glaucoma, Trabeculectomy
Ologen (OculusGen)-Glaucoma MMC Control in Pakistan
The purpose of this study is to compare the safety and effectiveness of the ologen (OculusGen) Biodegradable Collagen Matrix Implant and the MMC group in filtration surgery.
- Trial name
- NCT00472810
- Testing
- ologen collagen matrix in glaucoma filtering surgery, MMC in glaucoma filtering surgery
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Pro Top & Mediking Company Limited
Osteoarthritis, Hypertension
A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure
To assess the effect of naproxcinod vs. naproxen on arterial blood pressure patients with osteoarthritis and controlled essential hypertension
- Trial name
- HCT3012-X-111 (NCT00662610)
- Testing
- naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid
- Where
- 29 sites in United States
- Volunteers
- 120 people
- Sponsor
- NicOx
Stage 1 Hypertension
Bioactive Milk Peptides and Blood Pressure
The purpose of this study is to investigate the effects of bioactive milk peptides on blood pressure in mildly hypertensive subjects.
- Trial name
- NCT01031485
- Testing
- Milk peptides and plant sterols
- Where
- Finland
- Sponsor
- Valio Ltd
Osteoarthritis With Controlled Hypertension
Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension
This randomized study will compare the effect of lumiracoxib, ibuprofen and placebo on 24-hour blood pressure profile and on urinary excretions of eicosanoids in controlled hypertensive patients who have osteoarthritis.
- Trial name
- NCT00419796
- Testing
- Lumiracoxib
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Novartis
Pulmonary Hypertension
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00325442
- Testing
- Oral treprostinil (UT-15C) sustained release tablets
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 354 people
- Sponsor
- United Therapeutics
Essential Hypertension
Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
The purpose of this study is to evaluate the long-term safety and tolerability of the combination of aliskiren and amlodipine given to patients with essential hypertension.
- Trial name
- NCT01237873
- Testing
- Ali/Amlo 150/2.5 mg
- Where
- 13 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hypertension
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
- Trial name
- NCT07553442
- Testing
- ALN-AGT01 RVR, Zilebesiran
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Alnylam Pharmaceuticals